POS0382 THE CARDIOSTILL STUDY: A FRENCH OBSERVATIONAL RETROSPECTIVE STUDY ON CARDIAC INVOLVEMENT IN ADULT STILL'S DISEASE

Résumé fourni par la source

Background: Cardiac involvement in adult-onset Still's disease (AOSD) represents a relatively frequent and potentially severe complication. However, its predictive factors and management strategies remain poorly defined. We conducted a retrospective multicenter study to describe the manifestations, treatments, and outcomes of cardiac involvement in AOSD. Objectives: The aims of this work were to describe the clinical and paraclinical profile of patients with AOSD who present with cardiac involvement, to try to establish the predictive factors for developing a cardiac complication, and to assess the response to treatment. Methods: Patients were included from three different databases originating from French hospitals. All met the Yamaguchi and/or Fautrel criteria. Demographic, clinical, biological data, as well as treatmentof 66 patients with cardiac involvement (AOSD + C group) were collected, analyzed, and compared to those of 126 controls without cardiac involvement (AOSD – C group). Results: Cardiac involvement occurred at AOSD onset, before or during the diagnostic stage in 62/66 (94%) cases, before any specific treatment. The AOSD + C group had more active disease at diagnosis including more frequent odynophagia, hepatosplenomegaly, myalgia, macrophage activation syndrome (MAS), and pleural effusion (Table 1). Biologically, they showed higher levels of white blood cells, neutrophils, ferritin, and C-reactive protein (CRP). Cardiac complications included pericarditis in 36/66 (55%) cases (with tamponade in 6 patients), myocarditis in 29 (44%) cases, and non-infectious endocarditis in 1 (1%) case (Table 2). Cardiac symptoms were non-specific, more often presenting as chest pain (74%) or dyspnea (53%). Signs of right heart failure were present in 16% of patients, while 10% had no cardiac symptoms (cardiac involvement discovered during routine evaluation). Predictive factors for cardiac involvement included a high modified Pouchot score, hepatomegaly, pleural effusion, myalgia, and elevated CRP. Less than 50% of patients treated with glucocorticoids (GC) alone achieved complete remission, whereas 90-100% of those who combined GC with anakinra or tocilizumab achieved remission. Although 50% of patients were initially managed in intensive care units, there was no death. Conclusion: This study represents the largest reported series of AOSD patients with cardiac involvement. The fact that nearly 10% of patients were asymptomatic (raises the question of systematic screening, particularly in cases of highly active AOSD. Our findings support the early use of IL-1 or IL-6 inhibitors in combination with GC, along with multidisciplinary management. REFERENCES: NIL . Table 1Characteristics and manifestations of AOSD at diagnosis in patients with and without cardiac involvement.AOSD – C (n = 126)AOSD + C (n = 66)p-valueDemographyMedian year (range) of AOSD diagnosis2016 (1980 – 2023)2014 (1980 – 2023)0.824Male n/N (%)47/126 (37)31/66 (47)0.254Age at AOSD diagnosis (years): median [Q1-Q3]36 [25 – 52]30 [22 – 51]0.157Follow-up (months): median [Q1-Q3]20.5 [0 – 31]22.50 [9 – 57]0.360Classification criteria fulfillmentYamaguchi criteria92/126 (73)60/66 (91)0.007Fautrel criteria103/126 (82)60/66 (91)0.141At least one criteria126/126 (100)66/66 (100)-Clinical manifestations at diagnosisFever >39°C: n/N (%)126/126 (100)66/66 (100)-Arthralgia : n/N (%)110/126 (87)54/66 (81)0.420Arthritis n/N (%)49/126 (39)14/36 (39)1.000Sore throat n/N (%)72/126 (57)51/66 (77)0.017*Maculopapular rash n/N(%)88/126 (70)43/66 (65)0.617Lymphadenopathy n/N (%)39/126 (31)20/62 (32)0.989Hepatomegaly n/N (%)10/126 (8)21/62 (34)0.001*Splenomegaly n/N (%)10/126 (8)13/62 (21)0.020*Myalgia n/N (%)20/126 (16)35/66 (53)0.001*Pneumonia n/N (%)3/124 (2)1/66 (2)1.000Pleural effusion n/N (%)4/126 (3)46/66 (70)0.001*MAS n/N (%)2/126 (2)8/66 (12)0.003*Biological manifestations at diagnosisWBC (G/L) median [Q1-Q3]14 [11 – 18]23 [17.0 – 28.9]0.001*PMNs (G/L) median [Q1-Q3]11 [8 – 16]20 [14.1 – 26.9]0.001*Percentage of neutrophils % median [Q1-Q3]83 [74 – 88]89 [81.8 – 92.1]0.001*CRP (mg/L) median [Q1-Q3]132 [65 – 205]328 [225.25 – 401.25]0.001*SF (μmol/L) median [Q1-Q3]1649 [494 – 6529]3593 [1149 – 10908]0.001*Glycosylated ferritin (%) median [Q1-Q3]10.50 [8 – 18.25]9 [7 – 16]0.131Elevated enzyme livers, n/N (%)46/126 (36%)29/66 (44)0.397Modified Pouchot Systemic Score at diagnosisMean (SD)4 (1)7 (2)0.001* Table 2Characteristics of cardiac events in the AOSD + C group.AOSD + C group N=66Cardiac events n/N (%)Pericarditis36/66 (55)Myocarditis29/66 (44)• Of which myopericarditis18/29 (27)Non-infective endocarditis1/66 (1)Time of appearance of cardiac involvement: n/N (%)Before or during the diagnosis of AOSD62/66 (94)After the first year of diagnosis4/66 (6)Clinical cardiac manifestations n/N (%)Chest pain42/57 (74)Dyspnea30/57 (53)Right heart failure9/57 (16)Asymptomatic (incidentally discovered)6/57 (10)Examinations: n/N (%)Electrocardiogram abnormality32/57 (56)• T wave modification• 10 (31)• Diffuse ST shift• 10 (31)• PR segment under-shift• 6 (19)• Atrial fibrillation• 3 (9)• Complete heart block• 1 (3)• Right bundle branch block• 2 (6)High troponin levels23/33 (70)Cardiac ultrasound abnormality*48/57 (84)• Pericardial effusion• 36 (75)• Signs of tamponade**• 6 (13)• Left ventricular dysfunction• 5 (10)• 15 mm oscillating mitral valvular vegetation• 1 (2)Cardiac MRI abnormality25/29 (86)• Pericardial effusion• 5 (20)• Myocardial gadolinium enhancement• 20 (80) Acknowledgements: All the doctors who participated in the observational call of the Club of Inflammatory Rheumatism. Disclosure of Interests: None declared . © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.